← Back to Search

Single dose of DZD8586 for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Led By Frank Lee
Research Sponsored by Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 days after the last dose
Awards & highlights

Study Summary

This is a study in healthy adult participants. This is the first time this drug has ever been tested in human, and so it will help to understand what type of side effects may occur with this intervention. It will also measure the levels of drug in the body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 days after the last dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 days after the last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number and percentage of participants with adverse event, serious adverse event, clinically defined abnormal vital signs, laboratory values, ECG abnormalities
Secondary outcome measures
Plasma and urine concentrations of DZD8586

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Single dose of DZD8586Experimental Treatment1 Intervention
Single dose of DZD8586
Group II: Single dose of PlaceboPlacebo Group1 Intervention
Single dose of Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DZD8586
2021
Completed Phase 1
~70

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Dizal (Jiangsu) Pharmaceutical Co., Ltd.Lead Sponsor
2 Previous Clinical Trials
130 Total Patients Enrolled
Frank LeePrincipal InvestigatorFrontage Clinical Services, Inc.
1 Previous Clinical Trials
25 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants
2021. "A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05176873.
~19 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top